MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21

Vipin Yadav, Teresa F. Burke, Lysiane Huber, Robert D. Van Horn, Youyan Zhang, Sean G. Buchanan, Edward M. Chan, James J. Starling, Richard P. Beckmann, Sheng-Bin Peng, The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation Molecular Cancer Therapeutics. ,vol. 13, pp. 2253- 2263 ,(2013) , 10.1158/1535-7163.MCT-14-0257

Jeffrey A. Sosman, Kevin B. Kim, Lynn Schuchter, Rene Gonzalez, Anna C. Pavlick, Jeffrey S. Weber, Grant A. McArthur, Thomas E. Hutson, Stergios J. Moschos, Keith T. Flaherty, Peter Hersey, Richard Kefford, Donald Lawrence, Igor Puzanov, Karl D. Lewis, Ravi K. Amaravadi, Bartosz Chmielowski, H. Jeffrey Lawrence, Yu Shyr, Fei Ye, Jiang Li, Keith B. Nolop, Richard J. Lee, Andrew K. Joe, Antoni Ribas, Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib The New England Journal of Medicine. ,vol. 366, pp. 707- 714 ,(2012) , 10.1056/NEJMOA1112302

Elizabeth K. Ziemke, Joseph S. Dosch, Joel D. Maust, Amrith Shettigar, Ananda Sen, Theodore H. Welling, Karin M. Hardiman, Judith S. Sebolt-Leopold, Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6 Clinical Cancer Research. ,vol. 22, pp. 405- 414 ,(2016) , 10.1158/1078-0432.CCR-15-0829

Charles J. Sherr, David Beach, Geoffrey I. Shapiro, Targeting CDK4 and CDK6: From Discovery to Therapy Cancer Discovery. ,vol. 6, pp. 353- 367 ,(2016) , 10.1158/2159-8290.CD-15-0894

Shom Goel, Qi Wang, April C. Watt, Sara M. Tolaney, Deborah A. Dillon, Wei Li, Susanne Ramm, Adam C. Palmer, Haluk Yuzugullu, Vinay Varadan, David Tuck, Lyndsay N. Harris, Kwok-Kin Wong, X. Shirley Liu, Piotr Sicinski, Eric P. Winer, Ian E. Krop, Jean J. Zhao, Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors Cancer Cell. ,vol. 29, pp. 255- 269 ,(2016) , 10.1016/J.CCELL.2016.02.006

Maria Teresa Herrera-Abreu, Marta Palafox, Uzma Asghar, Martín A. Rivas, Rosalind J. Cutts, Isaac Garcia-Murillas, Alex Pearson, Marta Guzman, Olga Rodriguez, Judit Grueso, Meritxell Bellet, Javier Cortés, Richard Elliott, Sunil Pancholi, Christopher J. Lord, José Baselga, Mitch Dowsett, Lesley-Ann Martin, Nicholas C. Turner, Violeta Serra, Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. Cancer Research. ,vol. 76, pp. 2301- 2313 ,(2016) , 10.1158/0008-5472.CAN-15-0728

Anna E. Vilgelm, C. Andrew Johnson, Nripesh Prasad, Jinming Yang, Sheau-Chiann Chen, Gregory D. Ayers, Jeff S. Pawlikowski, Dayanidhi Raman, Jeffrey A. Sosman, Mark Kelley, Jeffrey A. Ecsedy, Yu Shyr, Shawn E. Levy, Ann Richmond, Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment Journal of the National Cancer Institute. ,vol. 108, ,(2016) , 10.1093/JNCI/DJV406

Ran Zhao, Bu Young Choi, Mee-Hyun Lee, Ann M. Bode, Zigang Dong, Implications of Genetic and Epigenetic Alterations of CDKN2A (p16INK4a) in Cancer EBioMedicine. ,vol. 8, pp. 30- 39 ,(2016) , 10.1016/J.EBIOM.2016.04.017

Amita Patnaik, Lee S. Rosen, Sara M. Tolaney, Anthony W. Tolcher, Jonathan W. Goldman, Leena Gandhi, Kyriakos P. Papadopoulos, Muralidhar Beeram, Drew W. Rasco, John F. Hilton, Aejaz Nasir, Richard P. Beckmann, Andrew E. Schade, Angie D. Fulford, Tuan S. Nguyen, Ricardo Martinez, Palaniappan Kulanthaivel, Lily Q. Li, Martin Frenzel, Damien M. Cronier, Edward M. Chan, Keith T. Flaherty, Patrick Y. Wen, Geoffrey I. Shapiro, Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors Cancer Discovery. ,vol. 6, pp. 740- 753 ,(2016) , 10.1158/2159-8290.CD-16-0095

Anna Vilgelm, Ann Richmond, Combined therapies that induce senescence and stabilize p53 block melanoma growth and prompt antitumor immune responses OncoImmunology. ,vol. 4, ,(2015) , 10.1080/2162402X.2015.1009299